<scp>B</scp>ritish<scp>A</scp>ssociation of<scp>D</scp>ermatologists' guidelines for the management of squamous cell carcinoma<i>in situ</i>(<scp>B</scp>owen's disease) 2014

C.A. Morton, Andrew Birnie, D.J. Eedy, J.R. Hughes, A. Sahota, A.J.G. McDonagh, D.A. Buckley, I. Nasr, V.J. Swale, C.E. Duarte Williamson,

British Journal of Dermatology · 2013 · 235 citations · 128 references

DOIFull text

Open access

Concepts

Abstract

The overall objective of the guideline is to provide up‐to‐date, evidence‐based recommendations for the management of squamous cell carcinoma (SCC) in situ (Bowen's disease). The document aims to update and expand on the previous guidelines by (i) offering an appraisal of all relevant literature since January 2006, focusing on any key developments; (ii) addressing important, practical clinical questions relating to the primary guideline objective, i.e. accurate diagnosis and identification of cases and suitable treatment; (iii) providing guideline recommendations and, where appropriate, some health economic considerations; and (iv) discussing potential developments and future directions. The guideline is presented as a detailed review with highlighted recommendations for practical use in the clinic (see section section 34), in addition to an updated patient information leaflet [available on the British Association of Dermatologists' (BAD) website, http://www.bad.org.uk]. The guideline also reviews erythroplasia of Queyrat (EQ)/penile intraepithelial neoplasia (PIN) and bowenoid papulosis, which have similar histology and are often diagnosed by dermatologists; however, a detailed therapeutic review of these conditions is beyond the scope of this guideline. This guideline does not offer treatment recommendations for vaginal intraepithelial neoplasia or perianal SCC in situ. The guideline development group consisted of consultant dermatologists. The draft document was circulated to the BAD membership, the British Dermatological Nursing Group (BDNG) and the Primary Care Dermatological Society (PCDS) for comments, and was peer reviewed by the Clinical Standards Unit of the BAD (made up of the Therapy & Guidelines Subcommittee) prior to publication. This set of guidelines has been developed using the British Association of Dermatologists' recommended methodology,1 with reference to the Appraisal of Guidelines Research and Evaluation (AGREE II) instrument (www.agreetrust.org).2 It represents a planned regular update of the previous BAD guidelines for the management of SCC in situ (Bowen's disease).3 4 Recommendations were developed for implementation in the U.K. National Health Service (NHS) using a process of considered judgement based on the evidence. The PubMed, Medline and Embase databases were searched for meta‐analyses, randomized controlled trials (RCTs) and non‐RCTs, case series, case reports and open studies involving SCC in situ (Bowen's disease) to September 2013; search terms and strategies are detailed in the Supporting Information. Additional relevant references were also isolated from citations in the reviewed literature, as well as from a specific targeted search for PIN. Each author screened their set of identified titles, and those relevant for first‐round inclusion were selected for further scrutiny. The authors then reviewed the abstracts for the shortlisted references, and the full papers of relevant material were obtained; disagreements in the final selections were resolved by discussion within the entire development group. The structure of the 2007 guideline was then discussed and re‐evaluated, with headings and subheadings decided; different coauthors were allocated separate subsections. Each coauthor then performed a detailed appraisal of the selected literature, and all subsections were subsequently collated and edited to produce the final guideline. The authors intend that the recommendations and quality of evidence reflect the full evidence base at the time of writing and may be read without the need for reference to earlier versions, although detailed discussion of older studies is not repeated here. It should be recognized that this new version may give disproportionate weight to references to newer publications and therapies. Where there are direct comparisons between therapies, these are generally discussed in the section relating to those deemed to be most efficacious. Recommendations take into account simplicity, cost and healing, as well as the type and validity of the published evidence base; for any treatment, there may be site‐specific differences in the recommended option. This document has been prepared on behalf of the BAD and is based on the best data available when the document was prepared. It is recognized that under certain conditions it may be necessary to deviate from the guidelines and that the results of future studies may require some of the recommendations herein to be changed. Failure to adhere to these guidelines should not necessarily be considered negligent, nor should adherence to these recommendations constitute a defence against a claim of negligence. The proposed revision for this set of recommendations is scheduled for 2019; where necessary, important interim changes will be updated on the BAD website. Bowen's disease is a form of intraepidermal (in situ) SCC, originally described in 1912,5 although the original lesions, located on sites that were not sun exposed, were possibly arsenic induced. Current practice is to consider Bowen's disease as synonymous with SCC in situ for lesions sited on nongenital areas. In line with reduced use of eponyms, we have used the term squamous cell carcinoma in situ (SCC in situ) throughout this updated guideline. Squamous cell carcinoma in situ typically presents as a well‐demarcated, erythematous hyperkeratotic plaque with an irregular border, characterized by full‐thickness epidermal dysplasia on histology. An annual incidence of 15 per 100 000 has been suggested in the U.K.6; however, this was based on U.S. data, which may reflect a higher incidence due to greater sun exposure.7 Peak incidence of the disease occurs in the seventh decade of life, and most studies have shown a slight female preponderance.8 9 10 11 The majority of studies report that SCC in situ occurs mainly on sun‐exposed sites, with more recent studies suggesting the most common site being the head and neck (29–54%)10 11 12 13; however, the lower limbs seem to be affected more in women than in men.8 11 14 Older, U.K.‐based studies have reported that the majority of patients (60–85%) have SCC in situ on the lower legs, which may indicate that the sun exposure pattern is different in countries with lower rates of sunshine.8 9 Less common variants include pigmented, subungual, periungual, palmar, genital, perianal and verrucous SCC in situ. In routine clinical practice the diagnosis is made on clinical grounds, perhaps with the aid of dermoscopy (showing glomerular vessels and scaling).15 16 17 If there is diagnostic doubt, or if confirmation is required before proceeding with a certain type of treatment, a punch biopsy be This is to a as the full of the and be to there is any disease to a for SCC in situ include (i) and and (ii) arsenic may in (iii) in (iv) there is an between and the development of SCC in this is by for has been in SCC in situ in from It that may be relevant with to development of SCC in situ on the and it has been in of and and or as or have been studies have suggested that of with SCC in situ may have previous or mainly cell carcinoma The an SCC in situ is similar to the overall of any overall of In the by a incidence of and a of in patients with SCC in situ as of of from data in of further SCC in situ or of reflect a common studies a of carcinoma of for SCC in and for In bowenoid papulosis, is SCC in situ has a higher of and these are from case series, may be by different of lesions to different and not take account of with SCC in situ have not or have been in primary Evaluation of treatment studies of SCC in situ is due to potential in to specific of and rates may with studies used clinical than to the of and, in most will treatment without to a for the treatment there is in studies due to different site and and of different of and treatment studies in may have in treatment of SCC in may different of with being by as and and the potential for at sites as the lower Current U.K. for of the not include treatment of SCC in all recommendations in this guideline are from literature on SCC in situ and of lesions, and are presented on the that the authors nor the BAD an are presented in a that the and then and that require more or or are not of these and to sites and is in of the treatment for squamous cell carcinoma (SCC) in situ. The suggested of the into account the evidence for of or time required for the healing, and of the or for based on studies or cases is not treatment of generally generally not generally should not be evidence to the potential for or at the affected not have a for SCC in situ. for or if or of the treatment for squamous cell carcinoma (SCC) in situ. The suggested of the into account the evidence for of or time required for the healing, and of the or for based on studies or cases is not treatment of generally generally not generally should not be evidence to the potential for or at the affected not have a for SCC in situ. for or if or recent review of for SCC in situ by the identified data for and therapies. The review that using is an treatment, more than not different from using a higher than there was in between and In some patients with lesions, on the lower of patients where is there is an for than In these cases use of an the and it (see is a treatment for SCC in situ and is available in the U.K. as a of the original studies were performed using different and The in clinical use is or for repeated if have been a of studies in recent the of with that of for then for was with and in a the treatment, of lesions by with with and with with rates discussed of patients in the and repeated if with a with with 12 in patients and in patients with of patients with were with with randomized for with in with epidermal patients SCC in situ and the data were not with the lesions with being a than those with of the patients with a at with the a all patients with a the was a been in situ at a in the between and lesions were with majority were using a of with the of lesions by with of patients and of data are similar to those of of clinical in which in patients It has been reported that the of may be by under use of as a or with a the and of the and in and It is available as a and has been used to SCC in although in the U.K. is for and It is generally well it does and to be prior to The best evidence a with for 16 in the An from the was that the hyperkeratotic lesions, suggesting that the was to the An clinical on patients were deemed for used a the lesions for up to a of 16 of treatment, of the SCC in situ lesions with a of of open on 16 patients with lesions on the lower used for up to 16 reported that of patients the the treatment lesions an of from reported that of patients were with SCC in situ were for to for lesions 9 and for from reported that of patients of with SCC in without any as a of of cases or case that different as be and also that be for with are typically those that the therapeutic studies that treatment may be to of has the potential to In the open discussed of patients of treatment due to has been reported in the treatment of SCC in situ in although of these reports have been of use in with of of are discussed in section section is a and of SCC in with the of in the rates for differences in the and with rates in the of in the series, that is used using a of of with a or up to of at of and may on the lower In the open a on between and lesions, more than of which were on the a of and of with from to In in a the use of a on lesions in lower rates of treatment and of lesions, with 12 the available studies it that the more of a of at or at the the of in treatment and the of are not lesions with than those with not as well as those with or may be in for patients to or treatment, the need of a against the potential of was with and in a discussed in section section In an earlier of the in patients to of using of on a was in of healing, and a lower with to have a with at 12 as and are more to in areas. and have higher rates and are more time to and has been as of the and most of with SCC in is by the of the using and give a of with suggesting a of often of treatment and rates be a of of 4 reported a of of a of studies have shown rates similar or to In a of and with involving was in terms of and of lesions were on the lower time to with was on the lower with on the lower for lesions, and reported was greater with were more with of a of although the was than that used by the authors in most studies of this In rates were for and for and for and the authors also that and required the clinic for these treatment This is a and treatment for SCC in situ of and located in suitable areas. It for of the diagnosis and confirmation of the intraepithelial of the and of the need to be The reported to of rates of an studies reported lower rates of of a of and of a of it is that should be an treatment, the evidence base is may be with may be for SCC in situ the in and for some cases of SCC in situ for may also be a for in or of patients has reported on for at head and neck this cases of head and neck SCC in situ. the cases previous and and been with more than all or or site as the for it be to be necessary or The overall for the patients was for primary and for for SCC in situ of the or more is under for by using with in routine is repeated and if have been described for in SCC in situ as with often the identification of lesions using the than clinical and a of in a recent in SCC in The for and of using and more on treatment and used in are reviewed in the BAD British Group guidelines on clinical rates of are reported of with of lesions of randomized with or in patients with in was for then the sites were with with treatment repeated of lesions required The rates the treatment were similar with all for for for results with or rates for all were similar with of lesions and similar of was in an open of of for in using a with of at open studies of and lesions by the and 17 and rates for of reported in previous guidelines with a of lesions in an open in patients or to have with at at of with a and with may be for lesions with of of lesions at with of at site does not to the of with in SCC in situ located on and SCC in situ was with in with and results at to reports treatment of SCC in situ on the subungual, in sites on the lower legs, and in the of and In a for or SCC in situ in with rates of at 4 more in the group of with in with SCC in situ is discussed in section section is in a that be by patients have also been used to SCC in although published are recent open of in patients with SCC in with an overall reported at 10 in situ with is used most however, a with reduced all in situ in case series, with all lesions a of 4 is a common for SCC in situ has been as with for In a the of a of in situ were with similar to for with a direct between and of with or in in situ and to any between the In a of of 12 sites in lesions were SCC in situ. overall in of in and to in of with is discussed a and generally patient with diagnosed SCC in situ with was diagnosed with at the site a treatment, it is the treatment the of have been used to SCC in with and a recent literature review that and include patient and healing, on the are that it be used to where are and it be used on the of lesions is reported on the lower was in a the authors to that should not be used on and reviewed the use of in SCC in situ lesions, with or to in which was to patient of and the and of with of on in of patients in this by of lesions to of the lower was by a of 11 patients with 16 lesions, in which a was with to the used were per for of SCC in situ has also been reported in lesions, with in all cases and in patients with disease a In a review of patients with SCC in lesions were in a and with The was in lesions were with a of with or which resolved within patient with SCC in situ of the with and and with and due to with disease the of for SCC in situ is to case reports and it is considered for more treatment sites the and review cases of SCC in situ with and a of although was in of patients with SCC in that used a in to SCC in situ in reported treatment in of with all of the lesions a of to of of a of was more than the of to SCC within of in a of 16 patients in situ) by with for up to a is typically with the there is the potential for of and was to treatment by a used as a final with of the In a case of all lesions and a of This review of the literature identified certain of and therapies, in case reports and series, where evidence is to a specific treatment of have been reported in case reports or of SCC in situ using an was shown to to in a in patient with of the of of prior to of to of the lesions, within on the 4 of of patients with in situ lesions with of a with a for and a of were if were not up for at or were to It was suggested that the the of the of the reported that patients with SCC in situ involving a to to as and also with all to in the and at as developed 4 and were at and and In a patient with SCC in situ of a involving with and although the was due to a when all were patient with a 10 SCC in situ with of by a of per In a further case where SCC in situ to with the subsequently with the authors to that by the of may have been with of 12 with repeated for a of in data for were The authors that be by with and the greater and in the patients with SCC in situ were with in treatment for in case due to lesions were on without a of of the results in a in the of with a in An was with to SCC in situ in patients with with clinical and 16 of the of the to is were to 14 patients with SCC in with a to treatment in all a was in certain cases and was more common with an was for up to to SCC in situ in 15 with in patients of was used to and SCC in situ in with in patient at for 10 to of in the patient of SCC in situ using an in situ with a of The treatment of and the treatment required treatment was performed using under for was clinical in of patients of was in Squamous cell carcinoma in situ in any of the or and as or or of the and or of the with and the or is the most common and it may also with and of the has been a of SCC in situ of the The of or a is of the to does the of does seem to be i.e. in the of The diagnosis to be of an diagnosis of a or a in a be open to and if the the for a biopsy should be a diagnosis of SCC SCC in situ may be with lesions of the of the it has been suggested that biopsy SCC in situ are best as if there is a has been in situ in SCC in and at cases have been reported to be with SCC the of as a of and patients and should be up for and of SCC is or is proposed for SCC in situ in the to of the to and when by may be used for the of the by or with a is in some as is for of the to and is This be by or the and has been with and for isolated or lesions where to SCC has described are in case reports of the use of and is a term that has been used to the clinical of Bowen's disease of the and bowenoid and are used are presents as or more on the of the and of the should be used to pigmented, and of the to have a higher than to into In to the lesions of in a in are most common on the the and and also be the of and are important in all of is an of the management of most cases of that is with to be more and with full‐thickness dysplasia with is and be more and on are reports of in with for the treatment of and be in cases with biopsy is to the diagnosis and should be before a for and more for as a is a for the treatment of and there have not been any clinical for include the use of or although of the evidence of on case that have been in the literature include or and Therapy a between (in of the higher of for in situ and of and by without for up to was in a of with under for of patients with of the with sites for an of however, patients or similar was in of 10 of patients with primary or treatment for carcinoma of the was in a of 11 with further In a using and in 10 patients with was in with in was in the patients of In has been used to include from the and the by a from the of the was reported to be in a of 10 with and their should be and screened for and The treatment should be should be treatment include and and of for SCC in situ will be affected by patient and to patient for therapies, and cost to the patient and and are available for the treatment of SCC in situ in with the to the in primary and is more is most often located in with and to Therapy will on the of of and of prior to data and on and of based on by the U.K. was published in and and in the treatment of SCC in the of diagnostic biopsy in all cases by was at to was on or biopsy were the by then with being the most although this was on more than in This not include the of or by the patient or their cost based on published data the cost of a diagnostic the cost of a SCC in situ to be for for and for which clinic to In from of lesions located on the lower of SCC in situ and was more than of the as well as direct and This was on with earlier studies that of a was in of the of the group and of the the cost for was for for and for for reduced of the therapies, the cost per was also lower with and than with In of in as well as will between In the of new therapies, and with in treatment recommendations since the guideline there should be or to the treatment recommendations in this guideline. are most from of the and changes the of therapies. updated evidence to in SCC in although in direct evidence of between the and for sites as the require offer to on case reports and or therapies, studies are required if we are to be to offer and recommendations on that all reviewed have and it is to consider the potential for by perhaps with or although a is to be of therapies, for and be considered for SCC in situ. Evaluation of the cost of and from more The potential of in SCC in situ and SCC In the patients with SCC in situ is there of the type and treatment In the patients with SCC in situ is there that a of was discussed with the In the patients with SCC in situ the was a than The of cases per is to in the results due to a and to between different to this may to all cases in the 12 This guideline update reviews the evidence for in common use for SCC in as well as and where the evidence is typically to case The quality of evidence is for and as well as a in this may be by the more required for newer and in common although with lower quality evidence should take into account evidence of and to the and patient therapeutic are for SCC in situ located the and for of treatment SCC, squamous cell practice of treatment SCC, squamous cell practice are to the for to the writing of the earlier of these Clinical Standards and the and randomized controlled with a of evidence should not be used as a for a controlled National for Health and Clinical of has as an for and has to from and has in the of and has in the and from and are of the guideline development group. of recommendations and quality of evidence.

References

128